Combining treatment options for higher risk myelodysplastic syndromes and chronic myelomonocytic leukaemia

Incidence of and predictors for early death in paediatric patients with acute promyelocytic leukaemia

Blinatumomab has promising effect on hard-to-treat, rare acute lymphoblastic leukaemia subtype

Rituximab plus chemotherapy improves outcomes in acute lymphoblastic leukaemia

First all-oral treatment for relapsed and treatment-resistant multiple myeloma

Experimental oral therapy for high-risk CLL shows promise

Ibrutinib to treat elderly patients with chronic lymphocytic leukaemia

Idelalisib combination therapy in relapsed or treatment-resistant CLL better than standard regimen

ASH 2015: New targeted therapies for haematological malignancies

Using epigenetics to manipulate cancer cells

Overcoming the barriers of the P53 dysfunction to cure blood cancers

Experimental oral therapy for ultra high-risk chronic lymphocytic leukaemia shows promise